#emtricitabine

People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.

Two cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP)

Two and a half years into a PrEP program in San Francisco, none of the more than 600 gay men taking Truvada have contracted the HIV.

People with hepatitis B can safely take Truvada as PrEP, as it does not lead to liver inflammation â€œflaresâ€ or other health probl...

Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.

Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.

Evidence of sexual acquisition of hepatitis C among gay men receiving PrEP at a San Francisco clinic has prompted a call for routine...

Viread (tenofovir) is highly effective at suppressing hepatitis B, even after an eight-year period.

Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...

AbbVie’s ’3D’ regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV

With $3.48 billion in sales of the hepatitis C drug Sovaldi, Gilead Sciences reported a second-quarter revenue of $6.53 billion.

Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hep C.

The Sovaldi/ledipasvir combination pill to treat hepatitis C does not have a clinically significant impact on five common HIV antiretrovirals.

Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...

The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses

The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with ?immune-toler...